50 Participants Needed

Palmitoylethanolamide for Bipolar Depression

AH
RM
Overseen ByRodrigo Machado-Vieira, M.D, Ph.D., M.Sc
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: The University of Texas Health Science Center, Houston
Must be taking: Mood stabilizers
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 3 JurisdictionsThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

The purpose of this study is to o evaluate the antidepressant efficacy of the PEA in Bipolar Depression and the association between antidepressant response with endogenous cannabinoids and cytokine levels

Research Team

RM

Rodrigo Machado-Vieira, M.D, Ph.D., M.Sc

Principal Investigator

The University of Texas Health Science Center, Houston

Eligibility Criteria

This trial is for individuals with bipolar depression. Participants should be currently experiencing a depressive episode within their bipolar disorder but otherwise in stable condition.

Inclusion Criteria

Medically and neurologically healthy on the basis of medical history, physical examination
I have been diagnosed with Bipolar Disorder and have a high depression score.
I am currently taking an FDA-approved mood stabilizer, with or without an antidepressant.

Exclusion Criteria

Acute high suicidal risk
I do not have any uncontrolled health problems affecting my brain.
Cannabis misuse according to clinical judgement
See 5 more

Treatment Details

Interventions

  • Palmitoylethanolamide
Trial OverviewThe study tests the effectiveness of Palmitoylethanolamide (PEA), an enzyme inhibitor, against Bipolar Depression. It compares PEA to a placebo and standard treatment options over time.
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: PEA plus Treatment as Usual (TAU)Experimental Treatment2 Interventions
Group II: Placebo plus Treatment as Usual (TAU)Placebo Group2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

The University of Texas Health Science Center, Houston

Lead Sponsor

Trials
974
Recruited
361,000+

Baszucki Brain Research Fund

Collaborator

Trials
8
Recruited
330+